title: Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.
abstract: Increased expression of genes, silenced by methylation of their promoters, could have relevance for increasing effects of not only interferons (IFNs) but also APO2L/TRAIL, cytotoxics and immunotherapeutics for melanoma and other malignancies. A resistant melanoma cell line, A375, lacked APO2L/TRAIL or apoptosis induction by either IFN-alpha2 or IFN-beta. However, apoptosis was induced by IFNs in A375 cells by 5-aza,2'-deoxycytidine (5-Aza-dC), evaluated based upon the postulate that promoter methylation might be silencing pro-apopoptotic IFN-stimulated genes (ISGs). RASSF1A, commonly methylated at high frequency in many tumors including melanoma, which we discovered to be also an IFN-regulated gene, was increased by 5-Aza-dC. RASSF1A was important in enhancing apoptotic effects of not only IFNs and APO2L/TRAIL but also cisplatin. Unraveling epigenetic regulatory mechanisms, as yet only partially identified, will result in new biological insights and improved strategies for therapeutic use of IFNs or ISGs such as APO2L/TRAIL.
authors: Taussig Cancer Center and Case Comprehensive Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, United States. bordene@ccf.org
authors: Ernest C
authors: EC
authors: Borden
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D017209:Apoptosis; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D020868:Gene Silencing; D006801:Humans; D007372:Interferons / Q000494:pharmacology*; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D007372:Interferons
references: Cancer Res. 1993 May 15;53(10 Suppl):2410-5
references: 7683574
references: Cancer Res. 1994 Mar 15;54(6):1422-4
references: 8137242
references: Oncogene. 1994 May;9(5):1361-5
references: 8152796
references: Cancer Res. 1994 Apr 15;54(8):2060-3
references: 7513608
references: J Natl Cancer Inst. 1995 Feb 15;87(4):257-64
references: 7535860
references: Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):211-5
references: 8552607
references: Cancer Invest. 1996;14(1):25-53
references: 8597888
references: Nat Genet. 2004 Feb;36(2):117-8
references: 14752520
references: Nat Cell Biol. 2004 Feb;6(2):129-37
references: 14743218
references: J Interferon Cytokine Res. 2003 Dec;23(12):745-56
references: 14769151
references: Gut. 2004 Mar;53(3):425-30
references: 14960528
references: Annu Rev Biochem. 1998;67:227-64
references: 9759489
references: Blood. 1999 Jun 15;93(12):4347-53
references: 10361133
references: Cancer Res. 2004 Nov 1;64(21):8109-15
references: 15520223
references: Semin Hematol. 2005 Jul;42(3 Suppl 2):S3-8
references: 16015502
references: J Interferon Cytokine Res. 2005 Sep;25(9):511-27
references: 16181052
references: J Leukoc Biol. 2005 Oct;78(4):898-908
references: 16037410
references: Cancer Res. 2006 Jan 15;66(2):653-8
references: 16423993
references: Mol Cell Biol. 2006 Mar;26(5):1888-97
references: 16479007
references: Cancer Res. 2006 Mar 1;66(5):2785-93
references: 16510600
references: J Leukoc Biol. 2006 Jun;79(6):1286-94
references: 16624932
references: Carcinogenesis. 2006 Jul;27(7):1341-8
references: 16501252
references: Cancer Res. 2006 Jul 1;66(13):6692-8
references: 16818643
references: Immunology. 2006 Jul;118(3):302-10
references: 16827891
references: J Clin Oncol. 2006 Aug 10;24(23):3771-9
references: 16801630
references: Clin Cancer Res. 2006 Aug 1;12(15):4619-27
references: 16899610
references: J Natl Compr Canc Netw. 2006 Sep;4(8):751-7
references: 16948953
references: Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14007-12
references: 10570189
references: Leukemia. 1999 Dec;13(12):1960-71
references: 10602416
references: Nat Genet. 2000 Mar;24(3):227-35
references: 10700174
references: J Immunol. 2000 Apr 15;164(8):4143-9
references: 10754309
references: Nat Genet. 2000 Jul;25(3):315-9
references: 10888881
references: Oncogene. 2000 Jul 13;19(30):3372-83
references: 10918594
references: Bone Marrow Transplant. 2000 May;25 Suppl 2:S88-95
references: 10933198
references: Semin Cancer Biol. 2000 Apr;10(2):73-81
references: 10936058
references: J Biol Chem. 2000 Oct 13;275(41):31805-12
references: 10924517
references: Genomics. 2000 Nov 15;70(1):113-22
references: 11087668
references: J Biol Chem. 2000 Nov 17;275(46):35669-72
references: 10998413
references: Nat Cell Biol. 2001 Feb;3(2):128-33
references: 11175744
references: Cancer Res. 2001 Apr 15;61(8):3225-9
references: 11309270
references: Clin Cancer Res. 2001 Jun;7(6):1821-31
references: 11410525
references: Blood. 2001 Oct 1;98(7):2183-92
references: 11568006
references: Nat Genet. 2002 Feb;30(2):181-4
references: 11799394
references: Dig Dis Sci. 2002 Jan;47(1):170-6
references: 11837720
references: Oncogene. 2002 Feb 14;21(8):1251-62
references: 11850845
references: Cancer Res. 2002 Feb 15;62(4):961-6
references: 11861364
references: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5
references: 11880635
references: Hematol J. 2000;1(1):7-14
references: 11920164
references: Nature. 2002 Apr 4;416(6880):552-6
references: 11932749
references: Br J Surg. 2002 Apr;89(4):418-22
references: 11952580
references: Mol Cell Biol. 2002 Jun;22(12):4309-18
references: 12024041
references: Nat Rev Genet. 2002 Jun;3(6):415-28
references: 12042769
references: J Clin Oncol. 1996 Oct;14(10):2666-73
references: 8874325
references: J Immunol. 1996 Nov 1;157(9):4100-8
references: 8892645
references: Cell Growth Differ. 1997 Mar;8(3):343-52
references: 9056677
references: J Clin Oncol. 1997 Jun;15(6):2351-8
references: 9196150
references: Oncogene. 1997 Jul 24;15(4):453-7
references: 9242382
references: Semin Oncol. 1998 Feb;25(1 Suppl 1):3-8
references: 9482534
references: Cancer Res. 1998 Jun 15;58(12):2489-99
references: 9635566
references: Cancer Res. 1998 Aug 15;58(16):3660-7
references: 9721876
references: J Mol Biol. 1998 Sep 25;282(3):585-99
references: 9737924
references: Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9
references: 15609471
references: J Invest Dermatol. 2004 Dec;123(6):1127-34
references: 15610524
references: Leuk Res. 2005 Mar;29(3):283-6
references: 15661263
references: Clin Exp Immunol. 2005 Mar;139(3):468-75
references: 15730392
references: Annu Rev Pharmacol Toxicol. 2005;45:629-56
references: 15822191
references: Cancer Res. 2005 May 1;65(9):3497-508
references: 15867337
references: Nat Immunol. 2005 Jul;6(7):722-9
references: 15951814
references: Cancer Biol Ther. 2003 Sep-Oct;2(5):552-6
references: 14614325
references: N Engl J Med. 2003 Nov 20;349(21):2042-54
references: 14627790
references: Ann Surg Oncol. 2003 Dec;10(10):1184-90
references: 14654475
references: Semin Oncol. 2002 Jun;29(3 Suppl 7):18-26
references: 12068384
references: J Immunol. 2002 Jul 15;169(2):847-55
references: 12097388
references: Cleve Clin J Med. 2002 Jul;69(7):529, 533-4, 536-8 passim
references: 12109636
references: J Biol Chem. 2002 Aug 9;277(32):28504-11
references: 12029096
references: Int Immunol. 2002 Oct;14(10):1225-31
references: 12356687
references: Clin Exp Metastasis. 2002;19(6):541-50
references: 12405292
references: J Immunol. 2002 Nov 15;169(10):5978-85
references: 12421984
references: Nat Genet. 2002 Dec;32(4):581-3
references: 12415269
references: Nat Genet. 2003 Jan;33(1):61-5
references: 12496760
references: Cancer Chemother Pharmacol. 2003 Mar;51(3):231-9
references: 12655442
references: Cancer Res. 2003 Apr 1;63(7):1639-43
references: 12670917
references: Tissue Antigens. 2003 Mar;61(3):211-9
references: 12694570
references: Cell Death Differ. 2003 Mar;10(3):356-64
references: 12700635
references: Clin Cancer Res. 2003 May;9(5):1721-7
references: 12738726
references: Apoptosis. 2003 Jun;8(3):237-49
references: 12766484
references: Oncogene. 2003 Jun 26;22(26):4118-27
references: 12821946
references: Anticancer Res. 2003 May-Jun;23(3A):2043-51
references: 12894577
references: Cancer Invest. 2003 Jun;21(3):394-9
references: 12901286
references: Cancer Res. 2003 Nov 1;63(21):7068-75
references: 14612497
references: Carcinogenesis. 2004 Mar;25(3):389-97
references: 14633663
references: Clin Cancer Res. 2004 Mar 1;10(5):1670-7
references: 15014018
references: Cancer Res. 2004 May 1;64(9):3137-43
references: 15126351
references: Oncogene. 2004 May 13;23(22):4014-22
references: 15064737
references: Int J Oncol. 2004 Aug;25(2):419-27
references: 15254740
references: Cell Death Differ. 2004 Aug;11(8):915-23
references: 15118763
references: Cancer Res. 2004 Aug 1;64(15):5270-82
references: 15289333
references: N Engl J Med. 2004 Sep 2;351(10):998-1012
references: 15342808
references: Cancer Res. 1982 Dec;42(12):4948-53
references: 7139598
references: Cancer Res. 1985 Feb;45(2):863-71
references: 3881175
references: J Interferon Res. 1986 Jun;6(3):189-98
references: 3745984
references: J Interferon Res. 1986 Dec;6(6):615-25
references: 2437222
references: Immunogenetics. 1987;26(1-2):92-8
references: 2440802
references: Clin Exp Immunol. 1987 Jul;69(1):107-15
references: 3652526
references: J Natl Cancer Inst. 1988 Apr 6;80(3):148-9
references: 2450206
references: J Leukoc Biol. 1989 Jan;45(1):29-34
references: 2463322
references: J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8
references: 2472488
references: N Engl J Med. 1990 Jan 11;322(2):77-82
references: 2294436
references: Cancer Res. 1990 Feb 15;50(4):1071-4
references: 2297754
references: J Interferon Res. 1990 Apr;10(2):141-51
references: 2140395
references: J Biol Response Mod. 1990 Aug;9(4):368-77
references: 2395002
references: Cancer Res. 1991 Mar 15;51(6):1684-8
references: 1998958
references: Cancer Res. 1991 Aug 15;51(16):4155-63
references: 1907881
references: J Interferon Res. 1992 Apr;12(2):131-7
references: 1374455
references: J Natl Cancer Inst. 1992 Aug 5;84(15):1185-90
references: 1378904
references: Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10557-61
references: 1438246